menu
    • menu
    [{"orgOrder":0,"company":"Helocyte","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Helocyte \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Helocyte","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"CMV-MVA Triplex Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Helocyte \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/ National Cancer Institute"},{"orgOrder":0,"company":"Helocyte","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"CMV-MVA Triplex","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helocyte \/ Helocyte","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/ Helocyte"}]

    Find Clinical Drug Pipeline Developments & Deals by Helocyte

    Menu

    Helocyte

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Helocyte

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Helocyte

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMV-MVA Triplex

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : City of Hope

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Righ...

                            Details : Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.

                            Brand Name : CMV-MVA Triplex

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : CMV-MVA Triplex

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : City of Hope

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Helocyte

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Helocyte

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMV-MVA Triplex Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : $3.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial P...

                            Details : The funding will be used for clinical studies of Triplex, a cytomegalovirus (CMV), universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine, being developed by Helocyte and City of Hope.

                            Brand Name : Triplex

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 15, 2023

                            Lead Product(s) : CMV-MVA Triplex Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : $3.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Helocyte

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Helocyte

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMV-modified Vaccinia Ankara Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $20.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institu...

                            Details : Triplex is a universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara viral vector vaccine engineered to induce a robust and durable CMV-specific T cell response to three immuno-dominant proteins.

                            Brand Name : Triplex

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 11, 2022

                            Lead Product(s) : CMV-modified Vaccinia Ankara Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $20.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth